Antonio F. Cruz

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company, which engages in developing, manufacturing and marketing medical products and technologies, within the areas of interventional oncology, wound closure and ophthalmology. The company was founded by William L. Hunter and Cruz F. Tony in 1992 and is headquartered in Vancouver, Canada.

Transition Therapeutics, Inc. develops novel therapeutics for disease indications. It operates through research and development of therapeutic agents segment. The firm's products include ELND005 for the treatment of alzheimer's disease, bipolar disorder and down syndrome. Its metabolic drug candidate is TT401 for treatment of type 2 diabetes and accompanying obesity. Transition Therapeutics was founded by Tony F. Cruz on July 6, 1998 and is headquartered in Toronto, Canada.

NeuroMedix, Inc. develops pharmaceutical products. The company makes therapeutic agents for the treatment of degenerative and inflammatory diseases of the central nervous system, such as Alzheimer's disease and multiple sclerosis. It also develops therapies for the treatment of other degenerative neuroinflammatory diseases, such as Parkinson's. NeuroMedix was founded in 2005 and is headquartered in Toronto, Canada.

Ellipsis Neurotherapeutics, Inc. develops pharmaceutical products for treatment and preventing of Alzheimer's disease and related disorders. The firm commercializes neurodegenerative disease therapeutics and diagnostics. The company was founded by Laurence Rubin in November 2004 and is headquartered in Toronto, Canada.

Founded in 1923, Mount Sinai Hospital (Canada) operates a hospital. The private company is based in Toronto, Canada.

BIOTECanada serves as a national association for Canada's health, industrial and agricultural biotechnology sectors. The company was founded in 1986 and is headquartered in Ottawa, Canada.

Treat U SA develops targeted nanotechnology-based platforms for the specific delivery of drugs in the oncology area. It offers PEGASEMP, a platform conceived for delivering a cytostatic agent specifically to the tumor microenvironment, targeting two distinct cell populations: the cancer cell and the endothelial cells from the tumor blood vessels. The firm operates through its offices in Cantanhede and Coimbra. The company was founded in January 2010 by Vera Moura and Sérgio Paulo de Magalhães Simões and is headquartered in Coimbra, Portugal.

Accel-Rx provides seed and start-up investment services to the new health sciences companies. It engages in leveraging investment support to the research and commercialization centers such as the existing health-related Centers of Excellence for Commercialization and Research (CECRs). The company was founded by Natalie Dakers in 2014 and is headquartered in Vancouver, Canada.